Department of Hepatology, Toranomon Hospital, Japan.
Department of Pathology, Toranomon Hospital, Japan.
Intern Med. 2020 Oct 15;59(20):2511-2516. doi: 10.2169/internalmedicine.5055-20. Epub 2020 Jun 23.
We report a 71-year-old man with non-B non-C chronic liver damage who had been regularly visiting our hospital since he was 38 years of age. He underwent three partial hepatectomies for hepatocellular carcinoma (HCC) diagnosed at 65, 67, and 71 years of age, respectively. A histopathological examination showed moderately-differentiated HCC, and chronic hepatitis with mild fibrosis stage in non-tumor areas. alpha-fetoprotein (AFP) and PIVKAII were not useful for the early prediction of HCC, but TERT promotor mutation (C228T) in serum cell-free DNA was useful. This is the first report on the importance of long-term follow-up in non-B non-C chronic liver damage, regardless of the fibrosis stage.
我们报告了一例 71 岁的非 B 非 C 慢性肝损伤患者,自 38 岁以来一直在我院定期就诊。他分别于 65、67 和 71 岁时因诊断为肝细胞癌(HCC)而行三次部分肝切除术。组织病理学检查显示中分化 HCC 和非肿瘤区域的轻度纤维化期慢性肝炎。甲胎蛋白(AFP)和 PIVKA-II 对 HCC 的早期预测均无意义,但血清游离 DNA 中的 TERT 启动子突变(C228T)有意义。这是关于非 B 非 C 慢性肝损伤长期随访重要性的首次报告,无论纤维化阶段如何。